Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

s and increasing their risk of developing treatment-related acute myeloid leukemia.

To understand if ibrutinib may be effective for elderly CLL patients and to identify which patients might benefit most from the drug, researchers enrolled 116 CLL patient participants in several treatment cohorts: patients who were never treated (the treatment-nave group), those who had received two or more prior therapies (the relapsed/refractory group), those who had relapsed within two years of treatment (the high-risk group), and those over age 65. Two oral dosing regimens (420 mg or 840 mg daily) of ibrutinib were used. The primary goal of the study was to determine the safety of the low and high doses; secondary objectives included efficacy, measures of the intensity of the drug's effect in the body, and the long-term safety of administering this therapy continuously until relapse.

The study found that response to therapy was high across the cohorts, with largely manageable toxicities. Previously untreated elderly patients responded best to the agent, with 71 percent experiencing a complete or partial response at either treatment dose. The same response was observed in 67 percent of the relapsed patients and 50 percent of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

The treatment regimen was generally well-tolerated, as only non-severe side effects were observed, including diarrhea, fatigue, chest infection, rash, nausea, joint pain, and infrequent and transient low blood counts. Investigators found no evidence of cumulative toxicity or long-term safety concerns with a median follow-up of 16 months for treated patients. These results demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL.

"As we learn more about how to target specific essential survival signa
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... The Canton Group, a leading web and ... today that Tim Dodge has joined the company as ... Canton Group as it implements an ambitious growth ... Tim is a tech industry veteran who has developed ... companies. Before joining The Canton Group, Tim was Vice ...
(Date:6/3/2015)... On the heels of a report predicting bioinformatics ... here to review news coverage about the report by ... the talent to become a world-leading center of the young ... data are collected and analyzed to help scientists discover new ... of a perfect storm for bioinformatics leadership,” said Dr. Owen ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Alberto Grignolo, ... at DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award ... level of excellence, and commitment to service on a ... Global Connector Award that annually recognizes one DIA member ... advanced the mission of DIA to foster innovation to ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Z-Medica®, LLC, ... today since June has been designated as National Safety ... the Tucson, AZ. Police Department for its commitment to ... personnel utilized their Individual First Aid Kits (IFAK) over ... involved in shootings, stabbings or traffic accidents. Each kit ...
(Date:6/3/2015)... 2015 Sitting at a computer for ... the back, neck, shoulders and/or wrists. This can lead ... addition, recent research links sitting for long periods as ... Fortunately, three inventors from Oakville, Ontario, are offering an ... , They have developed a prototype for a patent-pending ...
Breaking Medicine News(10 mins):Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2
... ... Fundraiser, RESEDA, Calif., Oct. 16 The Los Angeles ... to either,join or give a dollar when it hosts its eighth annual "Wells ... there,are 663,233 people in the country with that last name. "We,re always ...
... Operations, Security and, Maintenance Services ... ARLINGTON, Va., Oct. 16 Vangent, Inc., ... business process outsourcing,solutions, today announced it has ... and Decision Support (EIDS) Infrastructure,Operations, Security and ...
... discovered how HIV evolves over the course of a persons ... of full-blown AIDS. The findings could pave the way for ... disease process, before it takes a lethal turn, researchers say. ... mutates from the beginning of the infection until the end, ...
... to existing regimen may help, researchers say , TUESDAY, ... day as an added therapy, the epilepsy drug lamotrigine ... finds. , The 239 participants, aged 13 and older, ... countries. They were already taking one or two medications, ...
... Students from Local Public Schools for Career Development, ... (NYSE: AGP ) will host more than ... Support Center in Virginia Beach as part of ... effort,presented nationally by the American Association of People ...
... Book, Mommy, Where Do Customers Come From?, Enables Public To Give And ... ... 16 Mommy, Where Do Customers Come,From?, the new Internet marketing book ... splash in the publishing,world for its timely content and the author,s generous ...
Cached Medicine News:Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:UF researchers track genetic journey of HIV from birth to death 2Health News:UF researchers track genetic journey of HIV from birth to death 3Health News:Lamotrigine May Reduce Epilepsy Seizures 2Health News:AMERIGROUP to Participate in National Disability Mentoring Day 2Health News:AMERIGROUP to Participate in National Disability Mentoring Day 3Health News:New Jersey Entrepreneur Turns a Page for Four National Charities 2
(Date:6/3/2015)... -- Varian Medical Systems (NYSE: VAR ), world leader in ... in the Middle East with the ... Arabia . Varian Medical Systems Arabia, the result of ... launched today at a ceremony attended by local dignitaries and ... move represents the next step in our commitment both to ...
(Date:6/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/snzzg5/2015_strategies ... "2015 Strategies in the US Tumor Marker Testing ... Highlights of the Report Include , ... testing market. , Major issues pertaining to ... economic, regulatory, demographic, social and technological trends with ...
(Date:6/3/2015)... 3, 2015 Creekridge Capital, an independent, national ... channels by adding two new sales representatives. Sam ... Sales Manager and Stefanie Stark joined the ... comes to Creekridge with over 20 years of vendor ... Creekridge, Mr. Puma will be responsible for identifying, implementing ...
Breaking Medicine Technology:Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2United States Strategies in the Tumor Marker Testing Market 2015 2Creekridge Capital Strengthens Sales Team 2
... WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) ... placebo-controlled clinical trial of,CRx-150 in patients with ... a disease-modifying anti-rheumatic drug,(DMARD) to placebo plus ... the preliminary analysis of this trial, CRx-150 ...
... percent response rate achieved with VELCADE, lenalidomide,and ... -- Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported ... trials of VELCADE based,therapies that showed consistently ... (CR) rates in newly diagnosed,multiple myeloma (MM) ...
Cached Medicine Technology:CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
... workstations is designed for laboratories with limited ... automation platform for routine sample preparation and ... throughput, process consistency and safety. Windows ... you to control the robotic and liquid ...
... The Labcyte miniGene LD is a ... to 96-, 384- and 1536-well microplates. This ... 16 channel standard or wide orifice nozzle ... movement allow for accurate dispensing to a ...
... The QFill2 is the ideal system for fast, ... The pressure driven, pinch valve controlled dispensing mechanism, ... Whilst all of the components that come into ... dismantle, clean, and autoclave. The unique compact design ...
... an innovative reagent dispenser for plate ... fulfill the need for precise automated ... more, FlexDrop provides an efficient solution ... tedious task of plate preparation for ...
Medicine Products: